ALLK Stock Price, Allakos Inc Quote, Chart

Market Summary

USD1.06-0.01

Delayedas of 22 Apr 2024, 12:01 pm

-0.93%

ALLK Stock Price

View Fullscreen

ALLK RSI Chart

ALLK Valuation

Market Cap

94.0M

Price/Earnings (Trailing)

-0.51

EV/EBITDA

-0.55

Price/Free Cashflow

-0.8

MarketCap/EBT

-1.29

ALLK Price/Sales (Trailing)

ALLK Profitability

Return on Equity

-110%

Return on Assets

-76.23%

Free Cashflow Yield

-124.53%

ALLK Fundamentals

ALLK Earnings

Earnings (TTM)

-185.7M

Earnings Growth (Yr)

-45.5%

Earnings Growth (Qtr)

-37.1%

Breaking Down ALLK Revenue

52 Week Range

1.07

(Low)(High)

Last 7 days

-3.6%

Last 30 days

-18.3%

Last 90 days

-7.8%

Trailing 12 Months

-74.6%

How does ALLK drawdown profile look like?

ALLK Financial Health

Current Ratio

4.92

ALLK Investor Care

Shares Dilution (1Y)

2.56%

Diluted EPS (TTM)

-2.14

Tracking the Latest Insider Buys and Sells of Allakos Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 06, 2024	radford harlan baird	sold (taxes)	-43,391	1.35	-32,142	chief financial officer
Mar 05, 2024	tomasi adam	sold (taxes)	-68,244	1.44	-47,392	president
Mar 04, 2024	alexander robert	sold (taxes)	-104,947	1.48	-70,910	chief executive officer
Dec 04, 2023	paterson craig a.	sold (taxes)	-17,480	2.5	-6,992	chief medical officer
Dec 04, 2023	tomasi adam	sold (taxes)	-40,135	2.5	-16,054	president
Dec 04, 2023	radford harlan baird	sold (taxes)	-20,950	2.5	-8,380	chief financial officer
Dec 04, 2023	alexander robert	sold (taxes)	-61,882	2.5	-24,753	chief executive officer
Sep 05, 2023	tomasi adam	sold (taxes)	-54,839	3.01	-18,219	president
Sep 05, 2023	radford harlan baird	sold (taxes)	-28,628	3.01	-9,511	chief financial officer
Sep 05, 2023	alexander robert	sold (taxes)	-84,569	3.01	-28,096	chief executive officer

Which funds bought or sold ALLK recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	Allspring Global Investments Holdings, LLC	sold off	-100	-39,109	-	-%
Apr 16, 2024	Moisand Fitzgerald Tamayo, LLC	unchanged	-	-588	504	-%
Apr 11, 2024	Douglas Lane & Associates, LLC	unchanged	-	-14,775	12,664	-%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Mar 28, 2024	Newbridge Financial Services Group, Inc.	sold off	-100	-16.00	-	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	reduced	-43.36	-164	349	-%
Mar 11, 2024	VANGUARD GROUP INC	reduced	-0.31	1,474,920	8,887,900	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	103	886,439	1,501,130	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.4	14,898	90,210	-%
Feb 16, 2024	PRICE T ROWE ASSOCIATES INC /MD/	added	24.89	7,227,000	21,624,000	-%

Are Funds Buying or Selling ALLK?

Are funds buying ALLK calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ALLK

No. of Funds

Unveiling Allakos Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	deep track capital, lp	2.87%	2,510,736	SC 13G/A
Feb 14, 2024	logos global management lp	3.3%	2,900,000	SC 13G/A
Feb 14, 2024	citadel advisors llc	3.4%	6	SC 13G/A
Feb 12, 2024	price t rowe associates inc /md/	9.1%	7,920,708	SC 13G
Feb 12, 2024	price t rowe associates inc /md/	0.7%	638,102	SC 13G/A
Feb 02, 2024	rivervest venture fund iii, l.p.	0.0%	0	SC 13D/A
Jan 29, 2024	blackrock inc.	5.8%	5,116,088	SC 13G
Jan 26, 2024	deep track capital, lp	5.72%	5e+06	SC 13G
Jan 26, 2024	deep track capital, lp	2.87%	2,510,736	SC 13G/A
Jan 18, 2024	biotechnology value fund l p	5.2%	4,558,983	SC 13G/A

Recent SEC filings of Allakos Inc

View All Filings

Date Filed	Form Type	Document
Mar 19, 2024	144	Notice of Insider Sale Intent
Mar 14, 2024	10-K	Annual Report
Mar 14, 2024	8-K	Current Report
Mar 07, 2024	4	Insider Trading
Mar 06, 2024	144	Notice of Insider Sale Intent
Mar 06, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading
Mar 05, 2024	144	Notice of Insider Sale Intent
Mar 04, 2024	144	Notice of Insider Sale Intent
Feb 26, 2024	8-K	Current Report

Peers (Alternatives to Allakos Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	38.7B	6.8B	-1.66%	-28.18%	-8.22	5.66	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.2B	1.8B	-2.46%	-28.84%	-41.3	9.94	76.23%	61.08%
BMRN	16.7B	2.4B	4.57%	-8.46%	99.75	6.91	15.42%	18.43%
INCY	11.8B	3.7B	-10.11%	-29.11%	19.67	3.18	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-14.37%	-42.33%	-10.84	14.45	425.83%	18.94%
BBIO	4.4B	-	-13.59%	50.21%	-6.66	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-13.81%	-4.67%	-13.45	11.89	440.80%	-27.84%
ACAD	2.8B	726.4M	-9.91%	-15.82%	-45.22	3.82	40.45%	71.62%
ARWR	2.8B	240.7M	-20.67%	-25.33%	-9.32	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-10.64%	-8.42%	24.94	4.47	85.90%	-14.05%
NVAX	558.4M	983.7M	-17.39%	-51.52%	-1.02	0.57	-50.36%	17.16%
CRBP	409.4M	881.7K	-0.38%	387.14%	-9.18	466.16	-77.61%	-5.33%
INO	226.2M	4.9M	-10.29%	-2.81%	-1.67	46.49	-54.97%	51.71%
IBIO	6.0M	2.1M	59.81%	33.59%	-0.22	2.14	-13.45%	66.37%

Allakos Inc News

Latest updates

Allakos Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-14.1%	244	283	319	350	386	419	307	346	535	621	655	684	720	441	474	500	517	535	170	185	191
Current Assets	-17.6%	180	218	252	283	309	339	222	258	452	531	576	629	669	425	458	484	500	520	154	169	182
Cash Equivalents	-5.8%	66.00	71.00	67.00	94.00	87.00	205	82.00	36.00	155	274	204	170	207	104	154	136	41.00	309	36.00	31.00	34.00
Net PPE	-4.6%	33.00	35.00	36.00	38.00	39.00	40.00	41.00	44.00	43.00	40.00	25.00	14.00	8.00	7.00	8.00	8.00	8.00	8.00	9.00	9.00	9.00
Liabilities	19.8%	75.00	62.00	64.00	70.00	76.00	74.00	84.00	86.00	89.00	97.00	84.00	68.00	65.00	27.00	27.00	22.00	21.00	21.00	18.00	17.00	7.00
Current Liabilities	56.0%	37.00	23.00	24.00	30.00	30.00	28.00	37.00	38.00	40.00	41.00	34.00	23.00	22.00	19.00	20.00	14.00	13.00	12.00	9.00	8.00	5.00
Shareholder's Equity	-23.6%	169	221	255	280	310	344	223	260	445	525	571	616	654	414	447	478	496	514	152	168	184
Retained Earnings	-5.9%	-1,118	-1,055	-1,010	-975	-932	-889	-859	-809	-612	-518	-455	-398	-342	-298	-256	-217	-189	-164	-143	-124	-104
Additional Paid-In Capital	0.8%	1,287	1,277	1,265	1,256	1,243	1,234	1,082	1,070	1,058	1,043	1,027	1,014	997	712	703	693	685	679	295	292	288
Shares Outstanding	0.3%	88.00	87.00	87.00	87.00	85.00	56.00	55.00	55.00	55.00	54.00	54.00	53.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	288	-	-	-	121	-	-	-	3,237	-	-	-	2,156	-	-	-	959	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	17.6%	-24,288	-29,479	-32,594	-30,139	-46,786	-26,128	-32,770	-174,287	-65,377	-46,435	-49,782	-46,259	-34,415	-35,823	-25,072	-18,614	-19,111	-16,199	-14,423	-13,279	-12,649
Share Based Compensation	-3.1%	10,203	10,534	9,821	10,665	9,273	10,732	11,761	11,392	14,595	12,496	11,397	12,354	10,206	7,989	7,762	7,489	5,865	3,960	3,105	2,834	2,539
Cashflow From Investing	-36.0%	20,189	31,547	6,121	35,318	-71,477	7,687	78,059	57,412	-57,085	113,086	82,949	4,288	-137,525	-15,298	41,320	115,400	-249,862	-91,507	19,278	10,120	-5,330
Cashflow From Financing	-100.0%	-	1,070	-	1,458	190	141,279	66.00	347	864	3,813	800	4,783	274,814	1,526	1,708	789	8.00	380,054	138	963	4.00

ALLK Income Statement

2023-12-31

STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses
Research and development	$ 150,908	$ 265,081
General and administrative	45,148	57,348
Total operating expenses	196,056	322,429
Loss from operations	(196,056)	(322,429)
Interest income	10,347	3,673
Other income (expense), net	8	(1,196)
Net loss	(185,701)	(319,952)
Unrealized gain (loss) on marketable securities	334	(131)
Comprehensive loss	$ (185,367)	$ (320,083)
Net loss per common share:
Net loss per common share, basic	$ (2.14)	$ (5.06)
Net loss per common share, diluted	$ (2.14)	$ (5.06)
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Weighted-average shares of common stock outstanding, basic	86,798	63,284
Weighted-average shares of common stock outstanding, diluted	86,798	63,284

ALLK Balance Sheet

2023-12-31

BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 66,440	$ 87,217
Investments	104,354	192,569
Prepaid expenses and other current assets	9,095	29,057
Total current assets	179,889	308,843
Property and equipment, net	33,369	39,144
Operating lease right-of-use assets	24,136	30,225
Other long-term assets	6,216	8,208
Total assets	243,610	386,420
Current liabilities:
Accounts payable	1,764	4,832
Accrued expenses and other current liabilities	34,814	25,206
Total current liabilities	36,578	30,038
Operating lease liabilities, net of current portion	38,215	45,949
Total liabilities	74,793	75,987
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.001 par value per share; 20,000 shares authorized as of December 31, 2023 and 2022; no shares issued and outstanding as of December 31, 2023 and 2022	0	0
Common stock, $0.001 par value per share; 200,000 shares authorized as of December 31, 2023 and 2022; 87,750 and 85,387 shares issued and outstanding as of December 31, 2023 and 2022, respectively	88	85
Additional paid-in capital	1,287,156	1,243,408
Accumulated other comprehensive income (loss)	50	(284)
Accumulated deficit	(1,118,477)	(932,776)
Total stockholders’ equity	168,817	310,433
Total liabilities and stockholders’ equity	$ 243,610	$ 386,420

About Allakos Inc

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. In addition, Allakos Inc. is conducting preclinical studies for AK007, which polarizes tumor-associated myeloid cells and promotes anti-tumor immunity. The company was incorporated in 2012 and is headquartered in San Carlos, California.

CEO	Dr. Robert Alexander Ph.D.
WEBSITE	allakos.com
INDUSTRY	Biotechnology
EMPLOYEES	123

Allakos Inc Frequently Asked Questions

What is the ticker symbol for Allakos Inc? What does ALLK stand for in stocks?

ALLK is the stock ticker symbol of Allakos Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Allakos Inc (ALLK)?

As of Fri Apr 19 2024, market cap of Allakos Inc is 94.03 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALLK stock?

You can check ALLK's fair value in chart for subscribers.

What is the fair value of ALLK stock?

You can check ALLK's fair value in chart for subscribers. The fair value of Allakos Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Allakos Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALLK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Allakos Inc a good stock to buy?

The fair value guage provides a quick view whether ALLK is over valued or under valued. Whether Allakos Inc is cheap or expensive depends on the assumptions which impact Allakos Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALLK.